NCT02543879View on ClinicalTrials.gov

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Acute Myeloid LeukemiaAcute Myelogenous LeukemiaMyelodysplastic SyndromeNon-Hodgkin Lymphoma
Interventions
DRUG

FT-1101

FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level

DRUG

Azacitidine

Azacitidine will be administered per site's standard of care

Trial Locations (8)

21201

University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore

23985

Moffitt Cancer Center, Tampa

28204

Levine Cancer Institute, Charlotte

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

60611

Northwestern University, Chicago

77030

MD Anderson Cancer Center, Houston

90048

Cedars Sinai, Los Angeles

Sponsors
All Listed Sponsors
lead

Forma Therapeutics, Inc.

INDUSTRY